Big Cldea CONNECTpreneur

Virtual Rocket Pitch + Power Networking

January 30, 2025 | 11am - 1pm EST

Join Us At

The World's LARGEST investor pitch events

AGENDA

11:00 - 11:05 ам VIRTUAL NETWORKING

11:05 - 11:15 AM WELCOME & INTRODUCTIONS


TIEN WONG, Founder and Host, CONNECTpreneur Community
 SKYLAR RALLISON, Community Manager, CONNECTpreneur

11:15 - 12:00 РМ ROCKET PITCH SESSION

Companies will be introduced by: - DEBBIE CLINE Founder and Chief of Customer Success, Buzzy Rocket - SARA CLASPER Associate Attorney, NEXT powered by Shulman Rogers

12:00 - 1:00 РМ PRESENTING COMPANY BREAKOUT ROOMS & VIRTUAL NETWORKING

PRESENTING COMPANIES





Aquillius - Leah Villegas

i-Lumen - John VeLure



Novel Microdevices - Andrea Pais



Coagulation Sciences - Sheldon Goldstein



PredxBio - Dusty Majumdar



Propel IOT- Rick Burtner



TESS Energy Solutions - Michael Logan



Wayvee- Anton Timashev

SPEAKERS



TIEN WONG, CEO, OPUS8, INC. @tienwong

Tien is CEO of Opus8, an investment and advisory firm which helps technology companies and alternative investment fund managers raise capital. He is also Chairman of Lumious, a leader in corporate tech training and learning analytics, as well as Chairman of Lore Systems, a provider of network engineering, cloud computing, and strategic IT consulting.

In 1991, Tien co-founded and served as CEO of CyberRep, Inc. until its acquisition in 2003 by Affiliated Computer Services. CyberRep was one of the largest CRM outsourcing companies in the world with over 2,300 employees and \$80 million in revenue. Today, the CyberRep/ACS business unit is one of the world's largest call center operations, with nearly \$3 billion in revenue as divisions of Xerox, Conduent, and Continuum. CyberRep was ranked for 4 consecutive years in INC. Magazine's "Inc. 500" as one of the fastest-growing companies in the USA. CyberRep was profitable for 11 straight years and was backed by Allied Capital Corporation.

Tien is a recognized international expert in CRM, direct marketing, and BPO, having presented at dozens of industry events around the world on CRM and BPO topics. He has provided industry commentary on the ABC, Fox, NBC, CNBC, Maryland Public Television, and China's CCTV networks, as well as Time Magazine, The Washington Post, Inc. Magazine, and Success Magazine. He serves on several boards including the Montgomery County (MD) Economic Development Corp., Center for Innovation Technology GAP Fund's Investment Advisory Board, Junior Achievement, and Refraction. He was appointed by Governor Martin O'Malley to the 9-member Maryland Venture Fund Authority which allocates and manages over \$130 million of capital which is invested into top-tier venture funds and startups. He is an Entrepreneur in Residence at Georgetown University's McDonough School of Business, and a graduate of Dartmouth College.



SKYLAR RALLISON, COMMUNITY MANAGER, CONNECTPRENEUR

Skylar Rallison is a dynamic professional who wears multiple hats as the Community Manager for CONNECTpreneur and Business Analyst for Opus8. She graduated from The Marriott School of Business at Brigham Young University with a degree in Entrepreneurial Management. She has many years of experience in Business Management, Social Media Marketing/Management, Data Analytics, Business Leadership, and Project Management. With a diverse skill set and a passion for facilitating connections and driving business growth, Skylar thrives in the intersection of Community Management and Strategic Analysis.

Skylar enjoys her current role at CONNECTpreneur, which hosts the world's largest monthly investor pitch events as well as 1/2-day Forums with upwards of 900 RSVPs, featuring VIP guests, speakers, exciting presenting companies, and the best CXO to CXO networking on the East Coast. Skylar is pivotal in fostering engagement and building relationships within the investor and entrepreneur community. She creates inclusive digital spaces where members can share insights, collaborate on opportunities, and build a supportive network. Her role includes but is not limited to, team management, event coordination, project management, and marketing.

She also enjoys her current role as a business analyst at Opus8. Opus8 assists companies and fund managers (private equity, VC, and hedge funds) raise private capital from family offices, UHNW individuals, and institutions. Skylar leverages her analytical mindset and attention to detail to provide valuable insights for Opus8. Through her meticulous analysis of investment opportunities and industry research, Skylar helps drive informed decision-making, enabling Opus8 to curate high-quality events that bring together investors and promising ventures.



Breakthrough Drug of Choice for Atopic Dermatitis (Eczema)

Multi-Target Therapeutics™ A New Class of Drugs More Powerful Therapeutics

MANAGEMENT TEAM

- Neal Koller Chairman & CEO President & CEO, Board of Directors, life science businesses, **last exit at 16x**; Sr. Exec. Wyeth
- Steven Pentelnik President P&G Exec. managed **\$1B early tech portfolio**, global manager \$750M Beauty Care Products
- Gary Pekoe, PhD Chief Scientific Officer Director for several multinational pharma companies, led development & approval of 1st & market leading topical antibiotic **Bactroban**[®], lead clinical trial protocol writer for **Keytruda**[®], 20 years clinical and regulatory adviser to pharma
- Jazmyne Mink Regulatory Affairs Manager 8 years' experience with Alphyn's AB-101

OPERATIONAL PARTNERS

Eagle Analytic - Analytics Lab Emery Pharma - Chemistry & Microbiology Lab World Class Ethnobotanist World Class Botanical Chemistry & Analytics Lab DDL - Formulation and Manufacture PCCA - Formulation and Manufacture Multiple Geo-local Agri Partners TagOne - Supply Chain Management Accelagen - Regulatory and Clinical Trials (AUS) Symbio - Regulatory and Clinical Trials (US, EU) DLA Piper - IP and Legal Worldwide EisnerAmper - Finance and Tax (US) Artus GmbH - Finance and Tax (Australia)

SCIENCE ADVISORS

12 Global KOL Dermatologists

Dennis P. West, PhD

Prof Emer, Derm, Feinberg Sch of Med, Northwestern Univ

Peter Coderre FDA IND & NDA Microbiology Reviewer (retired)

Scientific Advisory Board, CARB-X (BARDA, NIAID, NIH) Antimicrobial Regulatory Consulting LLC

Patric Lundberg, PhD

Past Associate Prof, Microbiology/Molecular Cell Biology Eastern Virginia Medical School

Shekhar Mitra, PhD

Sr VP, Global Innovation, Procter & Gamble (retired) President, InnoPreneur, LLC

FUNDING TO DATE

Founders	\$ 870 K (not capitalized)
Seed	\$ 1.1 M (Convertible Note)
Pre-equity	\$ 2.5 M (Convertible Note)
Series A	\$ 5.5 M (Series A)
Non-dilutive	\$ 2.1 M

CURRENT SERIES B FINANCING

Series B \$18.0 M; **\$9 M raised** 2 liquidity event milestones funded Lead Investor in place, diligence available

SERIES B's 4 EXIT LEVEL MILESTONES

FUNDED - Complete Phase 2b AD Trial in AUS **FUNDED** – Increase to \$2.7B drug raw material asset Complete Phase 2b AD Trial in US & EU Complete 2nd drug Phase 2 Trial

COMPANY OVERVIEW

Alphyn is bringing a very important new drug to patients worldwide with its zabalafin (AB-101) drug platform to develop immuno-inflammatory topical therapeutics with fewer side effects, greater patient tolerability, and, that are more effective, initially for Atopic Dermatitis (AD). Zabalafin is a new class of drugs named Multi-Target Therapeutics[™] providing unique multiple mechanisms of action from multiple bioactive compounds for multiple ways to treat an individual disease, to be more effective, and multiple diseases to treat. Alphyn's 1st drug candidate, topical zabalafin hydrogel, completed 2 Phase 2a clinical trials in AD, a huge at <u>\$41 Billion commercial opportunity</u>. Clinical results better than competitive drugs point to "drug of choice" for this vast market ⁵ with 88 Million patient population¹. Phase 2b clinical trials for AD are projected to start February 2025. The Company has <u>US patent protection to 2042</u> with global applications in process. A powerful new published paper by KOL dermatologist influencers support zabalafin as drug of choice for AD.

THE PROBLEMS IN TREATING AD

- 60.5% of adults report severe itch, 55 % report inadequate disease control²
- 67% of children and 33% of adults report poor quality of life²
- 8.3-year life reduction with hospitalizations primarily due to AD bacteria-associated problems ³

THE PROBLEMS WITH CURRENT TREATMENT OPTIONS

- Steroids Side effects
- Injectables Painful, for children?
- Orals FDA Box Warnings, this drug with FDA warnings circulates throughout body
- Topicals FDA Box Warnings, Side effects, Not very effective

TWO SUCCESSFUL PHASE 2a CLINCIAL TRIALS: ZABALAFIN ADVANTAGES

- Most important itch superior to competition
- Only AD drug to directly treat itch and the critical Bacteria Component of AD
- 90% of patients report significant improvement in Quality of Life
- 35% better reduction in inflammation versus dominate market leader (IGA)
- Side effect reduction and patient tolerability superior to competition
- Strong safety data result is Phase 1 clinical trial not required; Phase 2 clinical trials start age 2
- Clinical results point to 'Drug of Choice' for AD

MULTIPLE MARKET PROTECTION STRATEGIES

- US patent protection to 2042: US & Global Filings, Composition of Matter, Methods of Use
- Regulatory exclusivity possible: 10 years USA, 8 years Europe & Japan
- No FDA generic drug competition possibility
- Estimated 15 year robust drug raw material supply protection: Quantity, Contracts, Regulatory

VAST AND GROWING AD MARKET

Drug (Company)	<u>Time on Market</u>	Annualized Sales 4	Estimated Patient # 5
Dupixent [®] (Sanofi)	4 years	\$7 Billion	~ 270,000
Opzelura [®] (Incyte)	2 years	\$556 Million	~ 151,400

<u>Acquired / Licensed</u>	
Proteologix (by J&J)	
Kyowa Kirin (by Amgen	I)
Kymab (by Sanofi)	

AD STRONG COMPARABLE EXIT DEALS

<u>When</u>	Exit: Cash plus Milestones	Exit Stage
May '24	\$850 Million + Milestones	Pre-clinical
Jun '21	\$1.25 Billion	Phase 2 clinical trial
Jan '21	\$1.45 Billion	Phase 2 clinical trial

Executive Summary

Aquillius Ventures' Fund I is a \$50M fund based in San Diego, CA focused on early-stage Med Tech and Life Sciences startups. We are looking to invest in pre-seed and seed rounds for startups based in the US.

Our **mission** is to improve human health and create a healthier planet, specifically by focusing on women, children, and the elderly.

What makes us unique

Over the past two decades we have developed the infrastructure to attract, develop, and scale startups from early stage to marketready.

Our vertical integration allows us to have visibility on development, risks, and goto-market strategies.





Fund

Portfolio

Size: \$50M Term: 10 years Inv. Period: 5 years Min. Investment: \$500k Terms: two and twenty

Total Investments: 40 Investments per year: 10 Avg. Portfolio Inv.: \$500k

Returns and Equity

IRR Range: 15% - 20% MOIC Range: 4X – 6X Target Equity: 10% - 25%





VALUE PROPOSITION:

Restoring Vision, Not Just Managing Disease: 50% of patients improve vision by 10+ letters within 90-days.

Huge Market Opportunity: 130.0 Million are afflicted with Dry-AMD and projected market value of \$68.5 Billion by 2029.

Derisked Investment Opportunity: Backed by US-based feasibility study and well-positioned for Class II De Novo clearance

Rare Exit Potential in Ophthalmology: Comparable acquisitions have yielded 12-15x returns in 3-4 years.

Company Background: Ophthalmology company that has pioneered 'Vision Restoration' in those with Dry Age-related Macular Degeneration (*Dry-AMD*).

Leadership Team: Senior Management team has led FDA clearance for 16 Class II and III technologies and held leadership roles in 5 companies that have been acquired and delivered \$850.0 million in shareholder value.

Scientific/Medical Consultants: Dr. Sophie Bakri, Chair of Ophthalmology at the Mayo Clinic, Prof. Tim Cackson, Head of Retinal Research at King's College UK, and Dr. Jason Slackter, Vitreous Retina Macula Consultants of New York, and Robert Warner (Former President of the Americas, Alcon).

Products/Services: The level electrical pulses through an electrodes placed on the eyelid and the back of the neck to improve cellular structure and function within key cells of the Retina – included Retinal Pigment Epithelial and Ellipsoid Zone.

Technologies/Special Know-How: i-Lumen's proprietary dual waveform algorithm and treatment delivery system generated unprecedented clinical benefit within 90-days of treatment as 50% of patients had improved vision of 10+ letters on the ETDRS eye chart.

Market: The global market opportunity is valued at US\$44.6 Billion in 2025 and is projected to reach US\$68.5 by 2029. AMD is the leading cause of blindness in those over age 60 and it affects 1 in 4 people. Globally, more than 130 million people have AMD.

Distribution Channels: i-Lumen's highly scalable business model represents an incremental revenue stream for Ophthalmology offices. The Medicare reimbursement rate for daily treatments is projected to be between \$1,000 to \$1,400. Coupled with clinical results, reimbursement will drive adoption and utilization.

i-Lumen will leverage a Lasic vision correction surgery revenue model – 'pay per treatment'. An electronic key provided for each treatment delivered will automatically invoice (\$400 per treatment) the physician practice. The device system is capital equipment and has a gross margin of 90%.

Competition: The treatment solutions available today, including Syfovre (Apellis) and Izervay (Astellas), which only slow the progress of the disease while vision loss continues. Unfortunately, these intravitreal injections have side effects that could include inflammation within the eye and advancing patients into late-stage, wet-AMD.

Exit Strategy: Acquisitions in Ophthalmology are generally pre-revenue and yield 12-15x returns. i-Lumen has initiated conversations with leading industry strategics (Alcon, Johnson&Johnson, Carl Zeiss, and Bausch&Lomb) regarding acquisition of the technology. Clinical data to support market clearance is projected in 3-4 years.

Quick Facts

Company Name: i-Lumen Scientific, Inc.

Contact: John VeLure (CEO/President)

Address: 3800 American Blvd. West Ste. 1500 Bloomington, MN 55431

Phone: 952-240-6023 *Email:* jvelure@i-lumen.com *Website:* www.i-lumen.com

Industry: Ophthalmology

Domain: Medical Device

Bank: Minnesota Bank & Trust

Law Firm: Fox Rothschild

Patent Estate: Fox & Rothschild 29 US Patents, 3 CN Patent, 3 EU Patent, 2 AU Patent

Auditor: Baker Tilly US, LLP

Number of Employees: Seven (7)

Leadership Team:

John VeLure *(CEO/President)* Meredith Mundy (Research) Tracey Henry (Regulatory) Thu-Ha Duncan (Manufacturing)

Amount of Financing Sought: \$22.0 Million

Current Investors:

Bios Partners, MedFocus, Alafi Capital, and Santen Ventures

Use of Funds: Pivotal Study and FDA Market Clearance

Deal Terms:

Series B Funding Round Convertible Preferred Stock 8.0% Cumulative Dividend Liquidation Preferences Anti-Dilution Provision Share price: US\$1.35

Valuation:

Pre-money: US\$31.5 Million Post-money: US\$55.6 Million

Participation Options:

Direct Investment: US\$500K min. Bios SPV: US\$50K min.

NOVEL MICRODEVICES





andrea@novelmicrodevices.com

At Novel Microdevices, we are revolutionizing diagnostics with our Next-Gen, Patent-Protected Point-of-Care PCR Platform, delivering lab accuracy, rapid results, and unmatched affordability.

The Challenge

Although accurate, Laboratory PCR tests take days to get the results. Whereas low-cost rapid antigen tests have poor accuracy, leading to false negative rates of over 50%. There are no rapid, accurate and affordable point-of-care diagnostic tests.

The Novel Dx Solution

A next-generation, patent-protected, rapid, affordable point-of-care PCR multiplex diagnostic platform for infectious diseases and more.





HIGH PERFORMANCE:	Demonstrated Lab-level accuracy with integrated magnetic bead sample extraction & 40-cycle PCR
RAPID:	Sample-to-answer in just <u>10 to 15 minutes</u>
AFFORDABLE:	Instrument COGs: \$500; Cartridge COGs: <\$5
SAMPLE & PATHOGEN AGNOSTIC:	Works with <u>any pathogen</u> (viruses, bacteria, fungi and protozoa) and <u>any sample type</u> including swabs, urine, blood, saliva
MULTIPLEXED:	<u>6-channel real-time detection</u> of 6 or more targets in a single test
SCALABLE:	Fast and easy to develop new assays for <u>rapid</u> pipeline expansion

Market Size

The global infectious disease diagnostics market is projected to grow from **\$36.1B in 2022** to **\$49.46B by 2029** (CAGR: 4.6%). Respiratory Disease Market: 7 Billion USD

Sexually Transmitted Diseases: 5 Billion USD

<u>Near-term</u> <u>Pipeline</u>

Respiratory Panel Flu-A/B/RSV/COVID-19 STD Panel

Chlamydia/Gonorrhea+Res

Controlled Launch 3Q 2025

Controlled Launch 2Q 2026

Razor/Razor Blade Revenue Model

This revenue model is supported by existing CPT reimbursement codes and marketed through multiple sales channels, representing a significant growth opportunity.



Proven Traction:

NIH Allergy and

Funding Raised: \$22.15M (Grants: \$10.4M from NIH, CARB-X, RADx; Equity: \$11.75M)

\$2.7 Million in Follow-On Funding from NIH RADx[®] after demonstrating lab-level performance data

Capital Raise

Investment Opportunity: Bridge/Series-A2 \$3 Million Use of Funds: GMP Manufacturing, Controlled launch

Why Now:

Comparable Success Stories:

Curiosity Dx: Acquired by BioRad for \$170M in 2022 (at design lock stage).

Genmark Dx: Acquired by Roche for \$1.8B in 2021.

The time is ripe for Novel Microdevices to capture the market and revolutionize diagnostics globally.



COAGULATION SCIENCES Breakthrough in Blood Transfusion Management

INTRODUCTION/ ONE-PAGE EXECUTIVE SUMMARY

Clinical Problem: Research indicates 40% - 59% of blood transfusions are unnecessary. This results in needless complications such as allergic reactions, lung injury, fluid overload, immune system damage resulting in infections, prolonged hospitalization, and shortened lifespan. Hospitals lose approximately \$800 for each unit transfused in the inpatient setting while insurance companies lose billions annually.

Unmet Need: Unnecessary transfusions occur most often during major bleeding. With existing diagnostic tests, it is difficult to determine which blood products to transfuse, in what amount, and even whether blood products are indicated at all. Limitations of existing tests include prolonged time to results, complex and cognitively challenging interpretation, non-specific information and minimal, if any, treatment guidance. There is an unmet need for an easy-to-use test to guide blood transfusion decisions. Key opinion leaders, blood bank directors, surgeons and anesthesiologists confirm the need for Coagulation Sciences' Multiple Coagulation Test System (MCTS).

The Solution: Coagulation Sciences has developed the Multiple Coagulation Test System (MCTSTM). The system performs 12-18 blood tests simultaneously, in a disposable cartridge, in approximately 10 minutes, at the point-of-care. It determines which treatments will stop bleeding. No other platform provides this information. Also, MCTS results are extremely easy to interpret.

Unique Selling Advantage: The fully-automated MCTS provides more useful information to guide transfusion than existing tests, and does so in ~ 10 mins.

Business Model: The MCTS is a platform, with a razor and razor blade business model. Addition of new therapies to the disposable cartridge can expand use from cardiac surgery to trauma and transplant surgery, and assessment of anticoagulants in doctors' offices. Revenue in year three of sales is projected to reach \$60M.

The Market: The global coagulation testing market is projected to reach \$7.88 billion by 2032. The MCTS will not simply enter the point-of-care market, but will at times also replace tests currently performed in hospitals' laboratories and doctors' offices, such as the PT and APTT.

Research to Date: In-vitro research validates the underlying technology. Currently, treatment is often empiric, as factor levels cannot be performed quickly. The MCTS provides more information than factor levels in \sim 10 minutes. Research at the Mayo Clinic confirms the relationship between coagulation factor deficiencies and bleeding after cardiac surgery, and results from the study will be used to improve the MCTS and build the GMP-platform.

Intellectual Property: Coagulation Sciences holds seven unique patents.

Summary: Doctors often select a treatment for bleeding based on an abnormal blood test result, but most tests are non-specific, and can require too much time, while some are difficult to interpret. MCTS results are available rapidly and are easy-to-interpret, and will aid physicians in the management of bleeding patients, improving patient outcomes and decreasing costs.

For information contact: Sheldon Goldstein MD, CEO <u>sgoldstein@coagulationsciences.com</u> 917-363-6542 4700 Independence Ave. Riverdale, NY 10471



EXECUTIVE TEAM

B. Dusty Majumdar, PhD CEO

Recognized business and commercial leader in Healthcare, Life Sciences and AI

S. Chakra Chennubhotla, PhD

Chief of AI, COO, Co-Founder Recognized leader in Computational and Systems Biology and Explainable AI

BOARD OF DIRECTORS

Stanley Marks, MD (Chairman) Chairman of UPMC Hillman Cancer Center

Bill Newlin Newlin Investment Company

B. Dusty Majumdar, PhD CEO

S. Chakra Chennubhotla, PhD Chief of AI, COO, Co-Founder

FINANCIAL INFORMATION

<u>Funding raised until now:</u> **\$14.5M** (\$7M non-dilutive)

Current Raise:

- Now closing \$2M for Series A-2 (participation preferred stock)

- Up-to \$20M Series B in 2025

USE OF PROCEEDS

Strategic and Technical Hires Expanding the Spatial Biology ecosystem World-class go to-marketing strategy

BANK AND LEGAL

PNC Bank, Pittsburgh, PA TroutmanPepper, Pittsburgh, PA (Corp) Goodwin Law, Boston, MA (IP)

Empowering Pharma to Accelerate Discovery and Revolutionize Clinical Trials

Today, there are significant challenges in managing cancer patients as available therapies only work for $\sim 20\%$ of the time. Moreover, 90% of the drugs fail to get to the market and it takes on an average 8 years of development. Tumor biology holds the key to predicting response/ resistance to therapy.

PredxBio is the only company unraveling the dynamics of the tumor biology from biopsy samples. PredxBio is powering next-generation cancer therapeutics with AI-driven spatial biomarkers, which delves into the mechanism of action of drugs and predicts the patient outcomes with close to 95% accuracy. Over the last 3 years PredxBio has empowered top 10 Pharma companies to accelerate discovery and revolutionize clinical trials across some of the highest mortality cancers. PredxBio's technology will impact the lives of more than 25 million cancer patients around the world.

PredxBio Investment Thesis

- Next generation platform for **derisking drug development** at the intersection of AI, Spatial Biology and Oncology beyond black-box solutions in the market
- Commercial traction with multiple Pharma clients with **current revenue of** ~**\$1M** from Genmab, AstraZeneca, Amgen, BMS, Abbvie, Kite/Gilead, and Jazz Pharma.
- Seasoned leadership, **100+ years of experience** incl. GE Healthcare, Exact Sciences, ASCO, IBM, Cernostics, Carnegie Mellon University, and UPMC
- Driving significant value for shareholders and hope for patients
- First mover and 15+ years of development to create a plethora of spatial analytics algorithms and explainable AI models that are **adaptive and agnostic** to any imaging platform, any disease, and any multi-modal datasets
- Solid moat around the use of Explainable AI to capture tumor heterogeneity, cell typing, and microdomain discovery with 10+ patents granted and expanding
- \$65B+ precision medicine market; early exit opportunity (~10-20X Return)
- Raised \$6.9M non-dilutive funding and pursued **milestone driven** seed rounds totaling \$7.6M from Keiretsu Capital, Keiretsu Forums (NW&R, N.Cal, London, Toronto), Newlin Investment Co., Innovation Works, Allegheny Health Network (AHN), Chemical Angel Network, and Sacramento Angels
- Partnerships with MD Anderson Cancer Center, UPMC, Univ. of Queensland
- Strategic partnerships: Fujifilm, Pictorlabs, SironaDx, iCura
- www.predxbio.com | info@predxbio.com



Propel IOT, LLC, Powered by AI

Name Richard L. Burtner, Founder, President & CEO Address: P.O. Box 538. Iron Station NC 28080 Phone: (c) 703-472-4707 Email: RickPropelGPSIOT@gmail.com

Management: The team has built 3 prior \$100+M SaaS Co EVs, leading to exits with 100+ years of experience in this space. Inc. 500 CEO (SkyBitz), also has been a basement start-up Founder at Bluestar Communications that raised Silicon Valley VC funding, grew to a \$1.2BN IPO registration within 2 yrs. of Series A and sold to Covad for \$160M, plus other M&A deal expertise

Industry: IOT Powered by AI SaaS Asset Management Wireless Market

Number of Employees: 5 (incl. Member Mgr) + Consultants. 10 Former Team Members Joining Upon Series A Rd. Closing.

Year Company Founded: April 2022 Legal Structure: NC LLC, Converting to a C Corp at 12/31/24

Law Firm: Wyrick, Robbins Raleigh, NC. Larry Robbins, Our Acct. Partner

Financing to Date: \$5.5M Financing 3 Yr. Plan: '25-'27

Equity Financing to Date: Common Accredited Individual Investors \$5.5M (Incl. Founder \$3+M)

Series A Round Financing: Round Size: \$3.5M (\$3M Institutional

\$500K Friends & Family Portion)

PROPEL IOT

Marrying GPS with IOT & AI "Power" for Customer Savings

Web Address: www.PropelGPS.com & www.PropelIOT.ai

Our Funding Ask: \$3.5M (\$3M Institutional & \$500K Friends & Family) Series A Equity Round

Business Description: Propel IOT provides affordable real-time movable asset management technology & information for SMB's better decision-making that leverages our patented SaaS GPS tracking & sensor monitoring platform powered by advancements in AI & IoT.

Refer to the Attached Page that Highlights the SMB CUSTOMER PROBLEM WE SOLVE; HOW WE SOLVE THIS SMB PROBLEM AND THE BENEFITS TO OUR SERIES A INVESTORS!

Value Proposition: We offer our SMB customers better service, better alternatives, and lower-priced solutions to improve efficiency and security with a compelling ROI. We also offer our investors a recurring revenue SaaS model with an efficient investment capital structure for exceptional IRR results.

Company Background: Our team has built 3 prior fast-growth SaaS businesses with over \$100+M Enterprise Values leading to exits. We have relevant market domain expertise, know customers plus their needs in our target markets & have already proven that our model works with revenue/marketplace acceptance. We have an entrepreneurial "Can Do" nimble customer focused & innovative Company culture, much like existed at prior successful entrepreneurial ventures that generated EXTRAORDINARY RESULTS such as SkyBitz (>50% compounded annual sales growth over 3-4 successive years when building to \$33MM revenue and over \$1M revenue per employee in Yr. 3 during the same period).

Products/Services: Refer to our website at <u>www.PropelGPS.com</u>. & <u>www.PropelIOT.ai</u> Additional solutions, product specification sheets, and summaries are available upon request.

Intellectual Property/Special Know- We have one granted patent and plans for five new provisional patents we will file during '25 once our Series A Round is completed. We expect that over the next 3 years, we will file additional patents as innovation warrants given our knowledge of our markets, innovative approach, and the strategic value creation that we recognize for our Company by filing patents that serve to add practical efficiency solutions for our SMB customers.

Markets: Our 3 Market Segments of Focus are Expected to Total \$2.2TR in '27. Serving SMBs are: (1.) Wide Area Supply Chain; (2.) Regional / Local Last-Mile Delivery Incl. Service Vans for Electrical, Plumbing, etc., and (3.) In Buildings at destinations such as Hospitals, Warehouses, etc. The CAGR of These Segments averages 10% per Year.

Sales and Marketing: We have 3 "sub-market segments" within Transportation, Logistics, and Telematics that we are pursuing. Our model is to have experienced sales professionals with whom our CEO has grown companies in the past join the Company incrementally as we grow. Currently, we have five dedicated employees. With the Series A Round, we will add ten more employees, most of whom have worked with our CEO. We will also add teaming partners & professional sales channel partner firms with experience in our targeted sub-markets to private label and/or promote our solutions. We also partner with a service-disabled veteran-owned small business as we pursue federal contracts.



TESS Energy Solutions Thermal Energy Salvage/Storage & Conversion System Bridge to Commissions from Sales pending!

Unique in the World Technology **DECEMBER 5, 2024**

UNIQUE Thermal Energy Salvage/Storage & Conversion: IP Licensing, Global Distributor moving to mass production.

TESS Energy Solutions is the Global Authorized Distributor and sole IP licensing Agent for TESS, with stake in the IP

- TESS reduces Energy consumption in large commercial and industrial facilities by 20-35%, which has been documented in \$50M worth of Canadian Generation 1-4 Research and Development deployments with zero hours of technology related downtime.
- TESS increases the output of all types of power generation 25-40%
- With Solar Thermal Concentrators, TESS can produce 20 mWh of power per day in less than half a football field.
- TESS Energy Solutions has early \$200M worth of pilot projects in preliminary engineering / project analysis stages with companies like LyondellBasell, TATA Steel, Novelis Aluminum, Guardian Glass and more. The sales cycle is about 4-6 months long and some are just beginning but some are nearing contract phase.
- TESS helps clients decarbonize, meeting ESG environmental goals while enhancing profitability. However, a thorough engineering analysis is required to gauge the value of TESS to the facility.
- TESS Energy Solutions has just completed an APP, the results of almost \$2M investment, that allows us to do as many as 1000 such analyses per month, where previously, manually we could only do 2-3/month.

Our partner TECH CO-OP in Houston, whose Joseph Wilson made Controls for Baker Hughes for 34 years, will process standing job/shop orders and lead the transition to mass production plant to launch by Q2/3 2025. \$3B worth of product/year. CAP RAISE FOR PLANT WILL MERGE LLC INTO 60% CONTROL OF PLANT AND EXPANSION

M.P. Logan and Associates, LLC dba TESS Energy Solutions has 200 Membership Units (shares) Class A (voting); \$50,000 each and Class B (non-voting) \$35,000 each. There are TEN Class A and FOUR Class B available. Distributions for both classes are paid equally and same time. \$500,000 for TEN Class A Units, guarantee principle, 100% ROI likely by Q3 2025.

Profit distributions from the first 500 1MW contracts are expected to begin no later than Q3 of 2025.

Over five years, each unit will earn \$2-5M, and likely more.

The founder, and minority shareholder, set the company up to yield short-term and long-term gains. Some of founder's profits will deploy TESS plus FOCUS solar thermal for the worlds' 2 billion people with no access to electricity.





Michael Logan, CEO **Tess Energy Solutions** 844-589-3681 409-682-3881 MichaelLogan@TESS.energy



IBM Bromont, Quebec, Canada

2007 ASHRAE Technology Award **First Place**

wayvee analytics

Company Overview

Wayvee Analytics is a retail tech company that helps brick-and-mortar stores improve customer experiences and optimize in-store operations through privacy-compliant emotion analysis. Founded in 2023, Wayvee uses patented RF-based sensors and advanced AI algorithms to deliver real-time insights on shelf engagement and overall store performance by analyzing customer satisfaction, purchase intent, engagement and foot traffic. By replacing outdated survey methods with emotion AI analytics based on customers emotional responses, Wayvee enables retailers to make data-driven decisions that increase sales, enhance customer satisfaction, and maximize ROI.

Leadership Team

Anton Timashev, Co-founder & CEO

ZERO10 and Sensemitter (co-founder), angel investor, and Veeam Software (former sales and product management).

Alex Ovcharov, Co-founder & CPO

Shazam Eastern Europe (product director), Sensemitter (co-founder), strong background in neuroscience, consumer behavior, and product development.

Problem Statement

Retailers are facing increasing pressure to improve in-store customer experiences, optimize operational efficiency, and generate actionable insights while respecting consumer privacy. Despite significant investments in smart retail technologies aimed at improving store performance — such as inventory management and daily operations—feedback mechanisms remain outdated. Traditional methods, like surveys, fail to provide real-time insights, and retailers are often dissatisfied with conventional Customer Satisfaction (CSAT) scores, which typically cover less than 0.1% of shoppers. The challenge lies in the absence of an advanced solution that can effectively and quickly capture feedback on the efficiency of these technologies. With the hardware smart retail market valued at over \$32 billion in 2023 and expected to grow to \$100 billion by 2032 with a CAGR 25%, Wayvee addresses this gap with its innovative solution.

Quick Facts

Website: wayvee.com

Email: anton@wayvee.com

Address: 155 E 56th St, New York, NY 10022, USA

Founding Date: August 2023

Industry: In-store Analytics, Retail Technology, Emotion Al

Number of Employees: 60, including former CERN physicists and neuroscientists

Amount of Financing Sought: Seed Round, \$4 million (with \$1 million already committed by founders)

Use of Funds: Scaling operations, expanding U.S. presence, securing partnerships, and marketing

Funds Raised Before: Pre-Seed Round, \$4.5M

Solution

Unique Selling Points

- Measuring customer satisfaction, purchase intent, foot traffic and engagement in real time.
- Using RF-based sensors to analyze customer emotional responses through heart rate, breathing, and micro-actions, anonymously converting these into actionable insights.
- Providing 100% shopper coverage without compromising privacy.

Key retail metrics Wayvee measures

- \circ $\;$ Customer satisfaction for every shelf and section.
- \circ $\;$ Purchase intent and emotional response metrics.
- Lost sales due to pricing or assortment issues.
- Footfall traffic, bypass numbers, dwell time, and engagement rates.

Traction

- Kaufland Innovation Hub Award Winner.
- o National Retail Federation (NRF) Conference 2025: Generated 450 leads, including Walmart and Sam's Club.
- Pilots with Cartology (Woolworths Subsidiary): Focused on in-store advertising analytics and shelf ROI measurement.
- Ongoing pilots with APAC-based retailers like Iroha Mart, Lenskart, and CJ Express.



Proven Success Metrics

- +11% sales uplift through dynamic pricing based on real-time purchase intent.
- +17% promotional revenue growth by optimizing store layouts and customer flow.
- 15x faster A/B testing for shelf assortment changes than traditional sales reports, leading to an 8% sales increase.

Total Addressable Market

Wayvee's TAM focuses on grocery and fashion retailers, with 250,000 stores in the U.S. Out of 1 million total retail stores, around 3,408 have annual revenues over \$100 million, which are our primary targets. Roughly 25% of these, or 900-1,000 retailers, make up our TAM in the U.S. Expanding globally, we can double this to 2,000 potential clients. By including other sectors like fast food, our TAM increases to 7,000 clients worldwide.

Competitors

Retail Next, ShopperTrak, V-Count, Xovis, Vayyar

Business Model

Wayvee generates revenue through SaaS licensing and device sales. Its modular approach ensures scalability for retailers of all sizes, with a main focus on enterprise-level retail chains.

PARTNERS



NEXT powered by SHULMAN ROGERS

NEXT disrupts the legacy legal industry by offering a broad range of fixed fee solutions (stand-alone products and annual legal plans) delivered by senior attorneys with valuable business expertise. NEXT solves the problem that startup and emerging growth companies face when launching their business as well as scaling: lack of access to predictable legal fees, seasoned attorneys, the latest technology and key business services. We use cutting edge technology platforms to deliver real efficiencies, transparency and a collaborative environment for clients, attorneys and investors. NEXT partners with its clients to de-risk their business and get to the NEXT level, together reaching each milestone of success. NEXT is powered by Shulman Rogers, a full-service law firm with nearly 100 attorneys offering superior service across a wide range of practice areas. The firm also offers robust personal services such as residential closings and trust and estate planning. Shulman Rogers has earned its reputation for providing quality representation, business insight and client value, serving as a highly attractive alternative to larger, higher-priced firms and smaller, less diverse firms. Learn more at ShulmanRogers.com.



ANTHONY MILLIN, NEXT CHAIR & PARTNER, SHULMAN, ROGERS

Anthony Millin is the Chair of NEXT and a trusted legal and business advisor to startup, early-stage, and emerging growth companies. As a corporate and securities attorney, a successful serial entrepreneur, and a venture capitalist, Anthony brings a unique legal and business perspective to advising his clients. Anthony understands firsthand what it takes to start, scale and manage a company, to successfully prepare for and run a fund-raising process, and to address the legal issues faced by a startup. Another specialized skill set Anthony brings to the table is his China-based experience, assisting early-stage and middle-market companies interested in conducting business in China or seeking direct foreign investment from China. Anthony also serves as a Venture Partner at Urban Us, a seed-stage VC firm. Contact Anthony at amillin@shulmanrogers.com.



AEG @enterprisegrowth

AEG is a values-based membership organization that creates personal and business growth through trusted relationships. As a "Time Machine" for business leaders, AEG accelerates trust and facilitates peer relationships to drive business development and personal growth. We connect three communities of midmarket CEOs, elite business advisors, and regional centers of influence. Through regular programs, education and community facilitation, AEG cultivates deep personal and business relationships, enabling fast, impactful connections, collaboration, and personal and business referrals.



MARK HAAS, CEO, AEG @MarkHaas

Mark Haas is Co-founder and CEO of AEG (Association for Enterprise Growth), responsible for strategy, operations, and expansion of its communities to 30 cities nationally. He was previously President of ROM a strategy and operations management consulting firm, advising CEOs and boards to include leadership training for Tanzanian energy executives, developing curricula to train consultants in 40 countries for an international bank, crafting strategy and innovative business models for \$120 million nonprofit, merging two scientific associations, re-organizing a biomedical research agency, facilitating development of WWIV military strategy, and of facilitating a global R&D strategy for the US Navy.



BUZZY ROCKET

Buzzy Rocket was founded 12 years ago with the mission to help startups grow and scale their businesses. Debbie and Victoria do this with their decades of marketing experience combined with their first hand experience founding, growing and scaling successful startups. They only work with 6 startups at any given time so they can provide 1:1 attention to you and your team. The Buzzy Rocket team is also made up of web developers, graphic designers and copywriters so they can help you easily execute the marketing strategy they create. Learn more about their services at BuzzyRocket.com.



MODUS CREATE MODUS CREATE MODUS CREATE

We built our company with an ethos of open source, recruiting and retaining the best individual contributors, regardless of location. We are thought leaders who share what we learn and help steer the direction of our open source communities of practice.

We're not just dreamers or doers; we're partners and teachers. We help you instill a culture of learning, innovation, and unlocked potential throughout your organization.

In short, we help you transform your products, platforms, and processes to facilitate organisation-wide digital transformation.

PAT SHERIDAN, CO-FOUNDER & MANAGING PARTNER, MODUS CREATE



Pat is focused on the intersection of design, technology, and business. He saw the need for a high-end product consulting firm built with open-source team design and the concept for Modus was born. Pat helps clients see new ways to tackle challenges with emerging technology and brings his unmatched passion to work every day. As a serial entrepreneur and active startup mentor, he's a co-organizer of NoVa.JS and NYC.JS. He is a 2011 graduate of Mind Share, received his MBA from Georgetown University, where he is currently an Entrepreneur-in-Residence, and holds a BFA from the Corcoran College of Art and Design, where he currently serves as an advisory council member for the George Washington University Columbian College of Arts and Sciences.

PRINCE WILLIAM PRINCE WILLIAM COUNTY DEPARTMENT OF ECONOMIC DEVELOPMENT

The Prince William County Department of Economic Development and Tourism works hard to create a probusiness, globally-competitive environment that generates new, high-quality, and sustainable job opportunities for our residents and destination-driven attractions for our visitors. The department engages in a broad portfolio of services, partnerships, and strategic alliances to benefit the business community, including small businesses, startups, and entrepreneurs.



CHRISTINA WINN, EXECUTIVE DIRECTOR AT PRINCE WILLIAM COUNTY DEPARTMENT OF ECONOMIC DEVELOPMENT

Christina leads the Prince William County Department of Economic Development, catalyzing investment, retention, and redevelopment opportunities in the second largest county in Virginia. By positioning the county as a leader in the fast-paced, evolving economy of the Washington, D.C. region, we are shaping stages for expansion and collaboration in key target industries.

With more than 20 years of economic development and private sector real estate experience, she is an expert in development programs including finance, incentives, and marketing. Prior to leading PWCDED, she led Arlington's Economic Development business investment group, leading retention, recruitment, and entrepreneurial support.



REFRACTION erefractionpt

Refraction is a leading nonprofit innovation hub in Northern Virginia, that provides mentoring, programs, and office space for startups and high-growth companies to help create jobs in the greater Washington region. In five years, more than 300 member companies have collectively raised over \$350 million in capital. Refraction's partners include Amazon, Cox, Dominion Energy, MITRE, Fairfax County, Arlington County, Loudoun County, Virginia Innovation Partnership Corporation, and Virginia Tech.

PARTNERS

ROBERT H. SMITH SCHOOL OF BUSINESS DINGMAN CENTER FOR ENTREPRENEURSHIP

DINGMAN CENTER FOR ENTREPRENEURSHIP, UNIVERSITY OF MARYLAND @UMD_Dingman

The Dingman Center for Entrepreneurship is a top-tier entrepreneurial institute recognized around the world as a leader in enterprise creation. The Dingman Center is continuously pushing the boundaries of teaching and learning with its focus on practical entrepreneurship, global innovation, and international classroom experiences. The Center promotes opportunities that provide maximum resources to start-up businesses in terms of ideation, execution, and financing; and that support its mission to take entrepreneurs "from the back of a napkin to the first \$1 million in financing."

KEIRETSU

FORUM

KEIRETSU FORUM «KeiretsuAngels Keiretsu Forum is a global investment community of acc

Keiretsu Forum is a global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors. Keiretsu Forum was founded in the San Francisco East Bay in California in 2000 by Randy Williams. Keiretsu Forum is a worldwide network of capital, resources, and deal flow with 53 chapters on 3 continents. Keiretsu Forum members invest in high-quality, diverse investment opportunities.



FITCI - FREDERICK INNOVATIVE TECHNOLOGY CENTER, INC @FITCInc

The Frederick Innovative Technology Center, Inc. (FITCI) is a business incubator and accelerator designed to cultivate entrepreneurship in Frederick, Maryland. FITCI specializes in the strategic business support of local entrepreneurs in the early stages of mostly science and technology-based businesses: Biotechnology, Information Technology, Renewable Energy, and Cyber Security. FITCI currently has two locations in Fredrick, MD, and 52 client companies.

BALTIMOREANGELS 👍 THE BALTIMORE ANGELS @baltimoreangels

The Baltimore Angels is an angel investor group based in Baltimore, MD. Founded in 2009, its mission is to invest profitably in the regional entrepreneurial ecosystem and advance early-stage innovators to the next stage of capital formation. Its vision is to be the most trusted resource for angel capital investment and entrepreneurial mentorship in the Greater Baltimore region. A new generation of angel investing comes to Baltimore. If you are a tech entrepreneur or community-minded investor, please be in touch with Baltimore Angels. This is not your father's (or your uncle's) investment group.



MARYLAND TECH COUNCIL VENTURE MENTORING SERVICES

The Maryland Tech Council Venture Mentoring Services (MTC VMS) program is one of the leading team mentoring services available in the state of Maryland that is both highly sophisticated and results-driven. It exists to foster an environment that encourages innovation while expanding financial and business opportunities for tech, cyber, and life science start-ups. The MTC VMS Program provides free team-based mentoring services to qualified Maryland-based tech and life science venture CEOs who are accepted into the program. Since the MTC VMS program began, more than 75 ventures have enrolled & \$100MM has been raised in capital & grants.



STARTUP GRIND-COLUMBIA, MD @StartupGrindDC

Startup Grind-Columbia, mid-Maryland Chapter is part of the largest global community for innovation, entrepreneurship, and the startup community. We're actively educating, inspiring, and connecting more than 2MM+entrepreneurs, 600+ cities, and 130+ countries. We nurture startup ecosystems through mentorship, advisory services, education, inspiration, access to capital, and most importantly, connecting members with the resources we need to have the best opportunity to grow phenomenally successful ventures.

PARTNERS

Angels + Life.Sci ANGELS + LIFE.SCI INVESTORS

Investors

Formed in 1996, the Angels + Life.Sci Investors Network is organized under NJAngels.net. We are a managerled, loosely organized network of investors and accredited Angels, Coaches, and Experts who Sponsor worldclass Entrepreneurs. Our colleagues have deep experience and technical domain expertise in all of the life sciences disciplines in which we are involved, including nanobio tools, materials, and devices: telediagnostics, augmented healthcare & remote patient monitoring, automation and robotics, & advanced chemistry for drug discovery.



GEORGETOWN ENTREPRENEURSHIP INITIATIVE

Entrepreneurship is one of the world's most powerful forces for positive change. Georgetown Entrepreneurship seeks to instill an entrepreneurial mindset in students, foster an entrepreneurial culture across the university, support the successful growth of alumni ventures, and leverage the power of entrepreneurship to make an impact in the world beyond Georgetown.



JEFF REID, FOUNDING DIRECTOR, GEORGETOWN ENTREPRENEURSHIP INITIATIVE, GEORGETOWN UNIVERSITY'S MCDONOUGH SCHOOL OF BUSINESS @Hoyapreneur

Jeff Reid is the Founding Director of the Georgetown Entrepreneurship Initiative and Professor of the Practice of Entrepreneurship at Georgetown University's McDonough School of Business. Reid is a catalyst for entrepreneurship and a well-known leader in entrepreneurship education. In 2009, Reid launched the Georgetown Entrepreneurship Initiative to catalyze entrepreneurial thinking and activities across Georgetown University and impact the growing DMV startup community.



RYAN & WETMORE, P.C. @RyanWetmorePC

Ryan & Wetmore is a full-service accounting and management consulting firm, servicing the Northeast/Mid-Atlantic region since 1988. What makes us different from other accounting firms is our proactive approach. We work hard to earn our clients' confidence by encouraging open communication year-round. This approach has enabled us to help clients become more efficient, more competitive, and more profitable. Through our numerous management engagements, we have become trusted, unbiased advisors.



PETE RYAN, CO-FOUNDER & PARTNER, RYAN & WETMORE

Pete co-founded Ryan & Wetmore in 1988, a 3 office, 35-person firm serving the Mid-Atlantic region. He currently works with clients to address tax, audit, and accounting issues. He also has significant experience in international tax matters and business consulting services. His expertise extends to Healthcare organizations, Construction and Real Estate, Government contractors, Technology, Manufacturing, and High Net Worth Individuals. Pete has served on the Board of Directors for several organizations. He is an active member of the Healthcare Advisors Association, the Real Estate and Construction Association, the CPA Manufacturing Services Association, the Virginia Transportation Construction Alliance, and the Construction Financial Management Association.



ENTERPRISE TRANSFORMATION SOLUTIONS INES LEBOW, FOUNDER AND PRINCIPAL @ilebow1

Ines LeBow is the Founder and Principal Startup Consultant at Enterprise Transformation Solutions (ETS), which advises entrepreneurs on how to position themselves for funding. Over the course of her 30+ years in the industry, Ines has helped companies secure more than \$800M in funding, led start-ups and turnarounds for companies with up to \$500M in revenue, managed 11 M&A transactions, and guided 9 companies to a successful exit. With expertise spanning Operations, Executive Leadership, and Mentoring, Turnarounds, Revenue implementation, Engineering, as well as Communications, Ines has helped many companies prepare for VC and angel investment.



January 30 Attendees As of 1 30 30

preneur preneur preneur preneur pogics, Inc. entures podevices sociences y Solutions alytics stics,LLC ure Group of Michael E. Adler ech lnc rrprises neur World Accessories LC
preneur logics, Inc. entures bodevices 1 Sciences y Solutions alytics stics,LLC ure Group of Michael E. Adler ech lnc urprises neur World Accessories LC
preneur logics, Inc. entures bodevices 1 Sciences y Solutions alytics stics,LLC ure Group of Michael E. Adler ech lnc urprises neur World Accessories LC
ogics, Inc. entures podevices n Sciences y Solutions alytics stics,LLC ure Group of Michael E. Adler ech Inc urprises neur World Accessories LC
ogics, Inc. entures podevices n Sciences y Solutions alytics stics,LLC ure Group of Michael E. Adler ech Inc urprises neur World Accessories LC
entures pdevices pdevices y Solutions alytics stics,LLC ure Group of Michael E. Adler ech Inc Inc Irprises Inc IAccessories LC
entures pdevices pdevices y Solutions alytics stics,LLC ure Group of Michael E. Adler ech Inc Inc Irprises Inc IAccessories LC
entures pdevices pdevices y Solutions alytics stics,LLC ure Group of Michael E. Adler ech Inc Inc Irprises Inc IAccessories LC
entures pdevices pdevices y Solutions alytics stics,LLC ure Group of Michael E. Adler ech Inc Inc Irprises Inc IAccessories LC
bdevices n Sciences y Solutions alytics stics,LLC ure Group of Michael E. Adler ech inc urprises reur World Accessories LC
n Sciences y Solutions alytics stics,LLC ure Group of Michael E. Adler ech lnc rrprises neur World /Accessories LC
n Sciences y Solutions alytics stics,LLC ure Group of Michael E. Adler ech lnc rrprises neur World /Accessories LC
y Solutions alytics stics,LLC ure Group of Michael E. Adler ech Inc rprises reur World /Accessories LC
alytics stiics,LLC ure Group of Michael E. Adler ech Inc rprises ieur World /Accessories LC
alytics stiics,LLC ure Group of Michael E. Adler ech Inc rprises ieur World /Accessories LC
alytics stiics,LLC ure Group of Michael E. Adler ech Inc rprises ieur World /Accessories LC
stics,LLC ure Group of Michael E. Adler ech Inc Inc irprises ieur World IAccessories LC
stics,LLC ure Group of Michael E. Adler ech Inc Inc Inc Inc Inc VAccessories LC
ure Group of Michael E. Adler ech inc irprises ieur World /Accessories LC
ure Group of Michael E. Adler ech inc irprises ieur World /Accessories LC
of Michael E. Adler ech Inc Irprises neur World Accessories LC
ech inc rrprises neur World 'Accessories LC
Inc irprises ieur World Accessories LC
rprises neur World Accessories LC
rprises neur World Accessories LC
rprises neur World Accessories LC
rprises neur World Accessories LC
eur World Accessories LC
eur World Accessories LC
Accessories LC
LC
LC
LC
LC
edical, Inc.
ry Solutions Group Inc.
al
LC
al Partners
1
ı
Automotive Specialties
s
x
NT
dia
olutions, Inc.
Financial Group
dia-Moneywise Digital
ding & Services
Bio, Inc.
ry College
sory
arth Ventures
elm
t Venture Holdings. Inc.
rs
Living
ative
apital
apital
/e
ting
gels Silicon Valley
rt. India Ltd.
rt. India Ltd. lutions
iutions
g of Myrd
ig of Myrd s Ltd

Andrew Stewart Matt Courtney Buff Ousmane Clara Andi Ashley Colleen Albert Cam Pierce Paul Denise Cagatay Lisa Rishabh Anish William Rhonda Hector Gladys Ashish Nisha George Samuele Mario Alexey George Joe Michael Art Laura Danijella Christoph Gib Dzmitry Cherie Mark Bradley Altan Peter Maria Idong Herb Sina David Paige Veronica Sansan Collin Ruben Adae Darren Uriel Io Cindy Kenneth Jack Ryan Robert William Anoushka Ricardo Duane Sristika Ricci Scot Thomas Kadee Jonathan Matt Robert Yuying Doug Joshua Yoav Weiqing Sirius Lamia Fred Mark Linda Sumedh Fizie William Guy Malcolm

Choi Christ Clark Coffey Colchagoff Conde Conti Contreras Cortes Crangle Crews Crowder Crowley Cruickshank Cuddeback Culcuoglu Curry Daga Das Davis Davis Del Castillo Del Pozo Deshmukh Devadoss DeVaux di Giuseppe Dmitriyev Dodge Donohue Doucas Dougan Downes Dragas Dressel Dunham Dzemidzenka Edilson Eklund Enneking Erginkoc Erin Ermolova Essiet-Gibson Ezrin Faridimehr Farley Fernandes Fey Fibri Flintoft Flores Fonseca Foo Foronda Fraley Frasier Frogson Fuhrmann Galemmo Galle Gandhi Garcia de Alba Gardner Gautam Giambruno Giambruno Gilbert Gittel Gleason Goldman Goodman Gosser Grant Greenberg Greenberg Gu Gu Guellif Gumbinner Haas Hagopian Hajare Haleem Halliday Hammer Handelsman

CEO CEO President of Public Safety Associate Producer CEO CEO President of Rev Generation Founder Account Executive Founder/Senior Partner VP of Product Innovation and New Ventures GP Investor Co-Founder Founder & President Co-founder Business Consultant Marketing Agency Owner Crew Leader Owner Chief Product Officer CEO CEO Venture Investor President CEO Founder CEO CFO retired Founder Investment Advisor Representative CEO CEO CEO Advisor CEO CEO/Founder Principal CIO CEO Senior Investment Associate Investment Banking Managing Director Principal CEO & President Founder and CEO President Head of Sales & Marketing and Co-Founder Principal Founder & CEO New Business Strategy Manager Founder Executive Assistant Membership Director CEO Sales Executive President Principal / Founder President CEO & Founder CEO Partner Founder President and Founder CEO CEO Associate Partner President Research Assistant Professor, Director of Student CEO Managing Consultant Engineering Consultant CEO Angel Investor | Advisor CEO Managing Partner CEO Founder Co-Founder Business Solutions Manager Partner AI Solution Engineer Executive Director

Beige LLC Office of Strategic Services, Inc. FiglioTech America's Real Deal RosettaHealth PayCruiser Obsecurity Labs BeyondBorders Pro Solutions, LLC Spectrum Business Converspeech LLC St. Jude Redstick Activate Venture Partners Carbon3 QCx Massive Bio Ccg RVision Digital **R&B** Maintenance LLC R&B Maintenance LLC Byond GDP Financial Strategies Aventior Inc VU Venture Partners DEVCO cod.eat Guide2Care Mechano Therapeutics Multiple Morpheus Advisors Arthroscopy Assn of North America The Lending Corporation LLC mimo.fit ACTA Thermal Technologies Exit Code Member Marketplace Inc PulseIQ, llc HTLF Mosaic D&C Innovation Works Weild & Co. The Idyeas Group Potomac Business Groap Enerytics N Brereton Medical Technologies SIMMER, Inc. Soundboard Venture Fund Wakefully Google RSF Supplies LLC MQi Aquillius Keiretsu Forum Southern California Frasier Executive Holdings Team Believe Fuhrmann Canital Robert Galemmo Consulting LLC DPS SIMMER, Inc. Meiogenix GSR Partners Skill FiglioTech FiglioTech Hortus Al Legalshield JW **Technical Interviewers** The City College of the City University of New York, Department of Chemistry AFC Astral Partners International Astral Partners International **Dasion Corporation** ImproVRise Héra care solutions K4 / G2 Development Partners AEG Hagopian Marketing Xalify Montgomery College Williams Mullen GT Edge AI Do It Right LLC/Active Angel Network

Michael David James Chris Marcia Sibylle Browning Mathew Elena Christian Oksana Mia Jennifer loel Rowan Joyce Kelsev Megan Sadiq Nabila Tracv Mahesh Jack Maya Brian Dave Andy Elchin Dr. Mohammad Gus Kyle Bruce Darius Brad Hilman Giselle Ben Ron Michael Alvin Joe Haseeb Ranna Rova Gene James Kimberly Ted Martin Janicia Velibor Khaled Nick Victoria Markus мD Rajnesh Aaron Dragos-Alin Nancy Norman Frank Bob Ines Zeke David Rick Joe George Charis Wei Kevin Katherine Manu Surbhi Michael Fil Dwayne Anthony Todd Rey Rev Abdelrahman Emilia Eugene Baloko Annie

Hanson Harding Harrises Herbert Hinderliter Hinshaw Hoffmann Huizenga Huntington Jacques Johnson Kersting Khosravifar Koprivica Kovacic Kozyreva Leimbach Lestingi Letscher Lightfoot Likourezos Lizzio-Hashime Macaluso MacLaughlan Magana Mahmoud Malcolm

Harris

Hart

Hauser

Herzog

Horm

Hotai

Hume

Hunter

Hurst

Idris

Inc

Ikram

Inturi

Isaacs Isaila

Iversen

Izuka

Jafarov

Jamal

Jones

Jones

Jones

Kain

Kamil

Katz

Kazel

Kellv

Kessler Khan

Khan

Kim

Kirwin

Klein Koblick

Koev

Koh

Koubaa

Krohn

kumar

Kvitek

Lacea

LaDieu

Lai

Lau

Leach

LeBow

Lee

Lee

Li

Liang

LNU

Logan

Lorinc

Luke

Magna

Maia

Maior

Makala

Kull

Kapoor

Consultant Business Development Manager General Partner CEO / Co-Founder SVP, Corporate Development & Partnering MD Sales Entrepreneur General Partner Founder CEO Founder CEO Managing Director Project Director Business Development Manager Controller Managing Director Founder CIO Founder Managing Director Chief medical officer CEO Venture Accelerator Co-Founder & COO Scientist CEO, Co-Founder VC Analyst CEO President and CEO CEO Founder & CEO CEO Managing Partner Managing Member CEO/Founder CEO Managing Partner Vice President, Technology EVP CEO Founder CO0 Chief Business Officer Vice President Manager Chief Strategy Officer Chief Growth Officer CEO Managing Partner Sr Venture Associate сто Chief Narrative Archetect Associate Founder Co-Founder Chief Administrative Officer BOD Founder & CEO Business Advisor CEO/Founder Investment Manager CEO CFO Advisor President & Founder Principal CEO Principal Co-Founder, Head of Growth Strategy Director of Marketing CEO Head of Growth VP of Product Innovation CEO Ceo President President Founder Consultant ceo President Founder/Owner

Optimum Dynamics LLC Nemphos Braue Global Catalyst Ventures Lifejoint Orthopedic Solutions Open Biopharma Research & Training Ringbolt Capital Emed Bootstrap Seed Fund, LP BalletBoutique Creative Analytics Ployer Animation Egaceutical gener8tor F3Tech Comparative Biosciences, Inc. SRS Roofing and Sheetmetal Cresthaven Realty consortium Langua NeuroEM Therapeutics Inc Syncaru Empower Growth Capital Prothya Vertical Solar LLC Venture Acceleration and Incubation Services Synergy Consulting Woodwell Climate Research Center BioWiz Laboratories, Inc Aquillius Chosen2Lead Score Pharma InfinityoneAI Salus CM Stealth Startup (Quantum/AI) Sentinel VC Kalliam Capital LLC Writeon, Corp Portfolio Operating Partners Next-Stage Development Group Tkxel Joseph Stone Capital InnoTech Precision Medicine, Inc Dragon Startups SFA therapeutics T-NeuroDx Net-AV Koev Brothers Aktivo Labs Enfinia Growth Partners AT Worthy Technology , Inc. Nicholas Companies LLC Go Global World Immungenetics AG Amplifi Consulting and Executive Strategy KiwiTech GolfingInnovations.com Byteflare Dipsea Capital US Medigene Keliomics Braintree Business Development Center Enterprise Transformation Solutions, LLC Genting WealthRyse Startup Portal Management Personnel Xchange Swish IP Johns Hopkins SoftRobot Ghostwriter Consulting Compozure Montgomery County Economic Development Corporation American University **TESS Energy Solutions** Athletica Core Source Technologies The Verse Profounda Health & Beauty MYER MYER RESEARCH USAM Stem Healthcare ImagineRx, Inc. Pvrethra Inc. LACH

Torngee Lois Tony Ariba James Court Samuel Subhi Jerome Bradley Anafi Adam Brendan Tony Lori Maha Elias Robert Yi Charlotte Tahl Rachel Michael Randi James Max Brenda Troy Marco John Tina Tanis Roy Kevin Maureen leff Yousof Charles Eta Jolly Georgia Sam Shantanu Michael Mi Pascal Michael Manabu Frazier Janice Williams Anthony Chioma Jean-Luc Meka Mike Kushtrim Yash Giuseppe Mhiel Tom Summon Jordan William Charlie Joel Patty Melissa Brian George Harsha Joe Ronald James Mark Arianna Joseph Teri Alexander John Gary Franklyn Robert Larry Rick Ruby Moniqua Nader

Malu Malu Mansfield Maqbool Marrug Marshall Martin Marwari Marzinski Mascarenhas Mataka Mayhew McAdams Mcanelly Mcanelly Mehanna Mendoza Mendralla Meng Meyer - Schönherr Milburn Miller Miller Miller Mitnick Mohr Montesinos Moore Morgado Morgan Moriarty Morris Morris Mullenex Mulvihill Musa Naderi Nahabedian Nahapetian Nanda Nerantzaki Nguyen Nigam Niggel Novac Ntez O'Brien Ohashi Oleary Oliver Omokha Ossai Park Parker Pawlowski Peci Pednekar Perale Peralta Perkins Pervaiz Piper Podd Porritt Price Pvtlik Quevedo R Radmilovic Rajasimha Reddix Redmer Redpath Reece Regalado Regalbuto Reitan Reynolds Ricci Robinson Rosario Rosenberg Rosenfeld Rosenthal Russell Russell

S

CEO Director of Admin CEO Distribution Business CEO & Cofounder Advisor Senior Analyst Founder and CEO CEO CEO Team lead Head of Business Development Founder COO Engineering Operations . Vice President, Business Development & Portfolio Partner President, Investments Founder & CEO Managing Partner Program Manager Senior Advisor President President Fundraising Team Lead **Business Owner** CSO Founder Managing Principal Chief of Staff Founder & CEO Partner CEO & Co-Founder Owner CEO CEO CEO Manager, Innovation Programs Founder University Graduate BDR Managing Partner Board member CEO Founder Managing Partner Assistant General Manager Chief inviter Founder/CEO Managing Director Social Media Marketer Sr. Director Social Impact Fund Founder CTO / Interim CEO Financial Advisor Founder Associate Cheif of Staff Director Client Accountant Data Analyst President CEO VP of Product Innovation Founder and CEO Director Co-Founder соо CEO and Founder President and CEO Managing Partner Managing Director CEO Investor Fellow CEO Owner Managing Director CEO Insurance Broker President founder Founder Founder Founder founder

EzzvCare EzzyCare Sterri-Matt Pty Ltd E-commerce Coresys Health Cynosure Connect OSF Ventures Stealth Startup OxSonics Prommuni Healthscape **Hive Analytics** Kiinetics **TESS Energy Solutions TESS Energy Solutions** XGen Pharmaceuticals DJB. Inc. Ubinnx **RM** Enterprises CoCarting App Seedfunders PenFed Foundation ToTheTop VenturEsq LLC AEC Online Store StartEngine Brenda Montesinos BioHSV Holdings Vicente Morgan Global LLC Malloy Industries Stealth STI iotaBEAM. Inc. Spacecraft Automation One Moxie Ventures deepcharge VK Digital Health Fairfax County Altheia Inc Gitlab Seedtob Capital ACT1 Federal InfinityOneAl MarketerZ Hub Síol Venture Capital Marubeni America Corporation KidBiz. Inc MisTee Wants To Know, Inc. Ares Management Karachi American School TEDCO GoNow Egg Healthy Pregnancy Merrill Lynch Nova Hustler Scampavia Bros. LLC Roval Belle Equity Blu Venture Investors Companion accountancy Landmark Family Office Russound Core Source Technologies SMILI HORUS Infinity 2immersive4u JEEVA Clinical Trials Inc The Reddix Group R-Squared Capital Partners Group LLC Cypress Associates LCMGroup **IDEA Fund Partners** Pegasus Angel Accelerator Strategic Merger and Acquisitions Hippogriff Consulting Us Angels PhaseDesign Research My Life Plan USA SMC McLean Partners Rick's Moving Co RR Distinctive Beddings LLC Core Health Education Genex

Amir Rovi Nina Hans Miguel Andrey Ivan Minnie Karisa James Alan mahesh Amenyo Mitesh Michelle Stephen Purv Shikha Ahmed Rebecca Todd Shav Rajiv Victoria Vibhuti Sanskriti Dave Andrew Svetlana Don Camille Tom Anne Rose Amine Jimmie Ernest Art Mythili Valentina lie Ning Ajay Rahul Jeremy Schantel Jim Tom Sam Imane Venkat Hubert Darryle Business Ben Chandra Shekhar Bharat Evan Chris Anthony Maoyue David Matthew Brad Monte B. Mitchell Ran Куо Archye Shashaank Roy Antoine Mikpongbeho Antoine Nishitha Jim Tom Igor Jeremy Beth David Priesnell Mike CeCe Barry Robert Skip Jeffrey

Director Sanam Sanchez Sanenko Sarana Sarwal Satterly Scampavia Schlaifer seethagari Setordzie Shaland Shapiro Sharma Sharma Shewbridge Shoemack Shoham Shrestha Silchenko Singhal Sirotkina Solitario Spencer Stapleton Stewart Subharam Sutherland Swain Dalcour Swanson Tabbara Tadakamalla Teicher Tekwani Thakkar Thomas Thompson Timmerman Tompkins Trotter Tzemach Vattikuti Vignon Viswanathan Voeller Vogelsong Volovich Wagner Walker Walkush Warren Watson Weeden Weinbaum Weissman Whitmore

Saberi

Saleh

Shah

Sheriff

Singh

Singh

Sinkoe

Small

Smith

Spear

Staali

Stern

Sulis

Sun

Sung

Suppal

Sutar

Swan

Tatra

Taylor

Team

Theiss

Tian

Tucker

Turley

Ueda

Valdes

Vella

Vignon

West

Wiggins

Laurie

Advisor President Project Manager Head of Delivery Freelance Founder Director President/Founder Chairman Innovation Specilist CEO Founder Founder US Partner Founder Sr. Director CEO CEO coo Founder and CEO CEO Strategic Business Development Analyst Founder CEO Associate Professor/Mentor Product Manager CEO CEO Founder/ CEO Co-Founder & CEO CEO Partner Executive Board Member Founder CEO Investor co-founder CEO Senior Business Advisor President Owner Business advisor President Founder & CEO Business Manager C-Suite Founder / Principal Executive Founder Founder Fractional CEO Business Development Strategic Business Partner Founder Partner Managing Director President, CTO Owner CEO Owner CEO CEO Founder/CEO Founder Ceo Investment Consultant Patent Attorney Startup Scout CEO CEO coo General Partner Managing Director CEO Financial Services Professional President President CEO CEO

Vita therapeutics Cynosure Connect NanTech Inspiralia VReal Soft Freelance Stealthbio PharPoint Scampavia Bros. LLC Wharton DC Innovation Summit, 11/06/25, WhartonDCInnovation.com Ziva Consulting Gladmen Consulting Limited Open & Async Projects LLC eHealth Ventures Apaux CLS Capture Biotech vcc PLA Dox Health, Inc. Metropole Capital Group TLE Calculus Capital Painvox Sesh Incorporated First Imagine! Ventures University of Wyoming, Laramie Elucid Tom, Inc. Plan Forward Phoenix Rising TV Provenmed Arcy Healthcare CM Law PLLC Vet Mentor Al OmicXHealth HKUST ChemT Sand Hill Angels The Webnect SLS Business Consulting Infinite CXO TJSwanson Co. TTP CWB-MSVU ITSYS Inc MMS Company Georgia State Research EpiFinder Cedarbrook Advisory CoreMobile.AI WattaCurrent Ltd. American University Blue Oak Consulting Elite Tech Fusion Inc Johns Hopkins University FullHorn Finance Curiate Sage Business Advisors HealthCare Markets Group Somnair Scaleup consulting Mirror Mii Inc. COUCHBROGAMES TrekMH Vella Ventures Analyticaxpress Analyticaxpress American University Maier & Maier K2X.capital RoadDoc IMPACT Social LLC The Verse Indigenous VC Frontier Business Advisory miruminvest.com-above10x New York Life

Suvarna Partners LLC MAXSA Innovations LLC Impact Proteomics Byond

Norelle	Wildburger	CEO / COO	Nanost / SynapsDx
Robert	Williams	Director of Growth	Refraction, Inc.
Larry	Wilner	CEO	The Strategies That Work
Pamela	Wirth	Founder	Hello Health
Eric	Wong	Founder	Myko Labs, LLC
Christian	Wood	Partner	GVG
Adam	Wrede	Account Manager	Actalent
Jim	Wu	Founder	SaniMed Science Group
Marcy	Wu	CEO	SceneX AI Group
Jessica	Wynter Martin	Founder	JWM Concepts LLC
Guoqiang	Xing	CEO	Lotus Biotech.com LLC
Lisa	Xu	Venture Partner	Tailwinds Venture
Alex	Y	CEO	Mynatek
Michael	Yan	Managing Director & Head of Technical Investments	Scrum Ventures
Yigang	Yang	Managing Partner	WaterStar Capital
Wayne	Yearwood	Creative Director	Dynamic Visions Graphix
Timo	Ylikangas	GP	Nordic Game Ventures
Susan	Young	Owner	Blue Dog Consulting LLC
Paola	Zaragoza Cardenales	Attorney	Zaragoza Cardenales
Joseph	Zecharia	Director, R&D	Actuated Medical, Inc.
Jian	Zhang	Partner	Bojian Captial LLC
Eva	Zhang	BD Associate Director	Base Therapeutics
Haoxin	Zhang	CEO	OpenMinds AI Medical
Annie	Zhao		
Juliet	Zon		

THANK YOU TO OUR PREP TEAM



LAURA HILL Chief of Staff Bentley



INES LEBOW CEO Enterprise Transformation Solutions



MARISSA LEVIN CEO Successful Culture International



JET LU Customer Solutions Amazon Web Services



JACKIE LUO Founder BAM Advisory



MICHELLE MILLER Founder MRM Consulting



JOHN MORGAN General Partner Morgan Global



EVAN SHUBIN Pres. and Founder Results.now, Inc. and Candlelight Partners



MALI PHONPADITH CEO SOAR Community Network



MICHAEL RIEMER CEO & Board Member Vocinity

SPONSORS

























KEIRETSU



startup grind

GEORGETOWSX Entrepreneurship Serving all of Georgetown University from the McDonough School of Business













ROBERT H. SMITH

DINGMAN CENTER for ENTREPRENEURSHIP

WANT TO PRESENT OR SPONSOR At our virtual events?

Email Skylar Rallison at srallison@opus8.com for more information

2025 Virtual Calendar

March	27 Ap	oril 24
May 29	June 26	July 31

REGISTER FOR OUR UPCOMING EVENTS

In-Person Event

February 6, 2025 Baltimore, MD



Virtual Event

March 27, 2025 Online via Zoom



<u>Virtual Event</u>

February 27, 2025 Online via Zoom



<u>View the</u> <u>RSVPs Here</u>



DRIVING DIGITAL INNOVATION WITH MEANINGFUL OUTCOMES



Modus Create is an end-to-end digital consulting firm. We bring multiple integrated skill sets and methodology expertise across software, product, and commercial platform domains. Our clients experience a boutique feel on an enterprise scale.

Our Practices and Offerings

DIGITAL STRATEGY

Making intelligent decisions about investments in technology.

PRODUCT Development

Building and enabling business-aligned applications that deliver stakeholder and customer value.

PLATFORM & CLOUD

Adopt a modern platform mindset, with scalable and secure architectures, tooling, and systems to increase quality and speed.

DIGITAL OPERATIONS

Operationalize collaboration, drive alignment in a single system of truth, and adopt modern methodologies for teamwork.

All four practice areas are powered by AI & DATA expertise throughout



Whether you're looking to innovate, scale, or transform, our team brings the right methodology and skill sets to drive your success.

Let's build the future together. Contact us today to get started!



CALL FOR PRESENTERS

Free lifetime admission to all CONNECTpreneur

Forums

Unprecedented **Networking sessions** before, during, and after each event

CONNECTPreneur

Post-event recap to 206k business leaders

in our Community

SCAN HERE FOR The in-person Brochure:



SCAN HERE FOR The Virtual Brochure:



Get funded with our Private Investor Platform

One of the nations largest investor communities of 4,500+ HNW/UHNW private investors, angels, family offices, investment groups, and small institutional investors.

Vetted, qualified, accredited Investors

Exclusive, cost effective, & reliable

> We guarantee our results



View the full brochure

Tien Wong CEO twong@opus8.com

Skylar Rallison Community Manager srallison@opus8.com



CONNECT WITH US!

